Biofrontera (NASDAQ:BFRI – Get Free Report) is set to issue its quarterly earnings data after the market closes on Wednesday, August 14th. Analysts expect the company to announce earnings of ($1.19) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Biofrontera (NASDAQ:BFRI – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.22). The firm had revenue of $7.91 million for the quarter, compared to analysts’ expectations of $11.52 million. Biofrontera had a negative return on equity of 1,390.99% and a negative net margin of 69.44%. On average, analysts expect Biofrontera to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Biofrontera Stock Performance
Shares of BFRI stock opened at $1.20 on Tuesday. The stock’s 50-day moving average is $1.03 and its two-hundred day moving average is $1.21. The firm has a market cap of $6.11 million, a price-to-earnings ratio of -0.11 and a beta of 0.46. Biofrontera has a 1 year low of $0.61 and a 1 year high of $10.40.
About Biofrontera
Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
See Also
- Five stocks we like better than Biofrontera
- Are Penny Stocks a Good Fit for Your Portfolio?
- How to Invest in Silver: A Beginner’s Guide
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- Using the MarketBeat Dividend Yield Calculator
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.